Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00BYM
|
|||
| Former ID |
DNCL002659
|
|||
| Drug Name |
Volasertib
|
|||
| Synonyms |
Volasertib; 755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 3 | [1] | |
| Company |
Boehringer Ingelheim
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C34H50N8O3
|
|||
| Canonical SMILES |
CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C
|
|||
| InChI |
1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25?,26?,28-/m1/s1
|
|||
| InChIKey |
SXNJFOWDRLKDSF-XKHVUIRMSA-N
|
|||
| CAS Number |
CAS 755038-65-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
15483372, 16819071, 40589122, 57654911, 79749962, 104249696, 124360769, 124757880, 125164682, 131549114, 134338771, 135264393, 135626900, 136340391, 136368049, 136920291, 137262652, 137275930, 139851906, 141803409, 141803412, 144115706, 152258397, 160647234, 162011969, 162038004, 162202619, 163351047, 163688738, 163908066, 170500071, 172919843, 184826692, 198980559, 223404364, 223705218, 227025640, 228302510, 235244922, 244755034, 246052840, 249565630, 252109940, 252160177, 252451595
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.